+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vivus - logo

VIVUS is a biopharmaceutical company that develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company’s lead product Qsymia is a combination appetite suppressant/stimulant and seizure medication indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in overweight and obese adults. VIVUS was founded in 1991 and is headquartered in Campbell, California.

Kainate Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Kainate Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
AMPA Receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

AMPA Receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Pulmonary Arterial Hypertension - Pipeline Review, H2 2020 - Product Thumbnail Image

Pulmonary Arterial Hypertension - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 412 Pages
  • Global
From
Hypertension - Pipeline Review, H1 2020 - Product Thumbnail Image

Hypertension - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 772 Pages
  • Global
From
Erectile Dysfunction Global Clinical Trials Review, H1, 2020 - Product Thumbnail Image

Erectile Dysfunction Global Clinical Trials Review, H1, 2020

  • Clinical Trials
  • January 2020
  • 477 Pages
  • Global
From
From
VIVUS LLC. - Strategy, SWOT and Corporate Finance Report - Product Thumbnail Image

VIVUS LLC. - Strategy, SWOT and Corporate Finance Report

  • SWOT Analysis
  • November 2023
  • 32 Pages
From
Vivus, Inc - Strategy, SWOT and Corporate Finance Report - Product Thumbnail Image

Vivus, Inc - Strategy, SWOT and Corporate Finance Report

  • SWOT Analysis
  • March 2022
  • 39 Pages
From
Loading Indicator